ArticleOncology letters2026
Immunotherapy combined with anti-angiogenic therapy, radiotherapy and chemotherapy for the treatment of giant pelvic osteosarcoma: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current therapeutic strategies for pelvic osteosarcoma remain limited, primarily relying on chemotherapy and surgery. Patients ineligible for surgery or those who develop chemoresistance generally have a poor prognosis. The present study reported the case of a 25-year-old female with giant pelvic osteosarcoma who missed the initial surgical window and developed lung metastases. Through a multimodal regimen incorporating chemotherapy, radiotherapy, anti-angiogenic therapy and immunotherapy, sufficient tumor control was successfully achieved to permit surgical resection. The patient maintained a stable condition with no signs of recurrence during follow-up until August 2025. This case underscores the potential of combining novel immunotherapeutic and anti-angiogenic agents with conventional modalities to convert inoperable pelvic osteosarcoma into a resectable state, thereby improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.